Observational studyFrontiers in neurology2026
Tracking migraine outcomes over time by age and monoclonal antibody type: a retrospective, single-center, real-world study.
Observational study in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are established preventive treatments for episodic and chronic migraine, but comparative longitudinal data across agents and age groups remain limited. This study aimed to evaluate long-term responses to different CGRP mAbs, assess whether age or treatment type influences response trajectories, and characterize multidimensional patterns of clinical response. Methods: We conducted a retrospective, single-center observational study including 453 adults with episodic or chronic migraine treated with erenumab, galcanezumab, fremanezumab, or eptinezumab between November 2018 and April 2026. Patients were stratified by age (<50 vs. ≥ 50 years) and different CGRP mAbs treatment. Longitudinal mixed-effects models assessed changes in monthly migraine days, acute medication use, pain intensity, disability, quality of life, and mood over 12 months. Generalized linear mixed models evaluated predictors of ≥50% response. Principal component analysis (PCA) was used to identify multidomain response patterns. Results: All CGRP mAbs produced rapid and sustained improvements across migraine frequency, disability, and patient-reported outcomes over 12 months. Age did not significantly influence baseline severity, longitudinal trajectories, or responder status. Treatment differences were modest overall; however, at 12 months, fremanezumab and eptinezumab were associated with higher odds of response compared with erenumab, while galcanezumab showed consistently higher response odds independent of time. PCA identified a Conclusion: In real-world clinical practice, CGRP mAbs demonstrate comparable and durable effectiveness across age groups. Subtle long-term differences between agents may emerge, particularly for multidimensional clinical improvement, supporting individualized treatment selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.